MBX Biosciences Common Net Income

MBX Stock   39.07  2.22  6.02%   
As of the 3rd of February, MBX Biosciences secures the mean deviation of 4.56, and Downside Deviation of 4.63. In respect to fundamental indicators, the technical analysis model lets you check practical technical drivers of MBX Biosciences Common, as well as the relationship between them.
MBX Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing MBX Biosciences' valuation are provided below:
Market Capitalization
1.7 B
Earnings Share
7.69
We have found one hundred eight available fundamental ratios for MBX Biosciences, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of MBX Biosciences last-minute market performance against the performance between 2010 and 2026 to make sure the company can sustain itself next year. Enterprise Value is likely to rise to about 740.3 M in 2026 This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
Last ReportedProjected for Next Year
Net Loss-55.7 M-58.5 M
Net Loss-55.7 M-58.5 M
Net Loss(2.13)(2.24)
Net Loss is likely to drop to about (58.5 M) in 2026. Net Loss is likely to drop to about (58.5 M) in 2026.
  
Build AI portfolio with MBX Stock
The evolution of Net Income for MBX Biosciences Common provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how MBX Biosciences compares to historical norms and industry peers.

Latest MBX Biosciences' Net Income Growth Pattern

Below is the plot of the Net Income of MBX Biosciences Common over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in MBX Biosciences Common financial statement analysis. It represents the amount of money remaining after all of MBX Biosciences Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is MBX Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MBX Biosciences' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (61.92 M)10 Years Trend
Slightly volatile
   Net Income   
       Timeline  

MBX Net Income Regression Statistics

Arithmetic Mean(32,263,888)
Coefficient Of Variation(39.57)
Mean Deviation9,373,593
Median(26,135,000)
Standard Deviation12,766,786
Sample Variance163T
Range35.8M
R-Value(0.69)
Mean Square Error90.8T
R-Squared0.48
Significance0
Slope(1,747,735)
Total Sum of Squares2607.9T

MBX Net Income History

2026-58.5 M
2025-55.7 M
2024-61.9 M
2023-32.6 M

Other Fundumenentals of MBX Biosciences Common

MBX Net Income Driver Correlations

Understanding the fundamental principles of building solid financial models for MBX Biosciences is extremely important. It helps to project a fair market value of MBX Stock properly, considering its historical fundamentals such as Net Income. Since MBX Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of MBX Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of MBX Biosciences' interrelated accounts and indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MBX Biosciences. Expected growth trajectory for MBX significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive MBX Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
7.69
Return On Assets
(0.17)
Return On Equity
(0.24)
MBX Biosciences Common's market price often diverges from its book value, the accounting figure shown on MBX's balance sheet. Smart investors calculate MBX Biosciences' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since MBX Biosciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that MBX Biosciences' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether MBX Biosciences represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, MBX Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

MBX Biosciences 'What if' Analysis

In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to MBX Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of MBX Biosciences.
0.00
11/05/2025
No Change 0.00  0.0 
In 2 months and 31 days
02/03/2026
0.00
If you would invest  0.00  in MBX Biosciences on November 5, 2025 and sell it all today you would earn a total of 0.00 from holding MBX Biosciences Common or generate 0.0% return on investment in MBX Biosciences over 90 days. MBX Biosciences is related to or competes with MeiraGTx Holdings, Replimune, ArriVent BioPharma, Ginkgo Bioworks, Iovance Biotherapeutics, MoonLake Immunotherapeuti, and Erasca. MBX Biosciences is entity of United States More

MBX Biosciences Upside/Downside Indicators

Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure MBX Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess MBX Biosciences Common upside and downside potential and time the market with a certain degree of confidence.

MBX Biosciences Market Risk Indicators

Today, many novice investors tend to focus exclusively on investment returns with little concern for MBX Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as MBX Biosciences' standard deviation. In reality, there are many statistical measures that can use MBX Biosciences historical prices to predict the future MBX Biosciences' volatility.
Hype
Prediction
LowEstimatedHigh
33.0639.0745.08
Details
Intrinsic
Valuation
LowRealHigh
23.7929.8042.98
Details
Naive
Forecast
LowNextHigh
25.7731.7937.80
Details
5 Analysts
Consensus
LowTargetHigh
55.6061.1067.82
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as MBX Biosciences. Your research has to be compared to or analyzed against MBX Biosciences' peers to derive any actionable benefits. When done correctly, MBX Biosciences' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in MBX Biosciences Common.

MBX Biosciences February 3, 2026 Technical Indicators

MBX Biosciences Common Backtested Returns

MBX Biosciences is somewhat reliable given 3 months investment horizon. MBX Biosciences Common has Sharpe Ratio of 0.18, which conveys that the company had a 0.18 % return per unit of standard deviation over the last 3 months. We have analyzed twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.09% are justified by taking the suggested risk. Use MBX Biosciences Common mean deviation of 4.56, and Downside Deviation of 4.63 to evaluate company specific risk that cannot be diversified away. MBX Biosciences holds a performance score of 14 on a scale of zero to a hundred. The firm secures a Beta (Market Risk) of -0.35, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning MBX Biosciences are expected to decrease at a much lower rate. During the bear market, MBX Biosciences is likely to outperform the market. Use MBX Biosciences Common semi variance, as well as the relationship between the daily balance of power and period momentum indicator , to analyze future returns on MBX Biosciences Common.

Auto-correlation

    
  0.85  

Very good predictability

MBX Biosciences Common has very good predictability. Overlapping area represents the amount of predictability between MBX Biosciences time series from 5th of November 2025 to 20th of December 2025 and 20th of December 2025 to 3rd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of MBX Biosciences Common price movement. The serial correlation of 0.85 indicates that around 85.0% of current MBX Biosciences price fluctuation can be explain by its past prices.
Correlation Coefficient0.85
Spearman Rank Test0.7
Residual Average0.0
Price Variance18.86
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

MBX Accumulated Other Comprehensive Income

Accumulated Other Comprehensive Income

43,266.66

At this time, MBX Biosciences' Accumulated Other Comprehensive Income is fairly stable compared to the past year.
Based on the recorded statements, MBX Biosciences Common reported net income of (61.92 Million). This is much lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is notably higher than that of the company.

MBX Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MBX Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of MBX Biosciences could also be used in its relative valuation, which is a method of valuing MBX Biosciences by comparing valuation metrics of similar companies.
MBX Biosciences is currently under evaluation in net income category among its peers.

MBX Biosciences ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, MBX Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to MBX Biosciences' managers, analysts, and investors.
Environmental
Governance
Social

MBX Fundamentals

About MBX Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze MBX Biosciences Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MBX Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MBX Biosciences Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for MBX Stock Analysis

When running MBX Biosciences' price analysis, check to measure MBX Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MBX Biosciences is operating at the current time. Most of MBX Biosciences' value examination focuses on studying past and present price action to predict the probability of MBX Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MBX Biosciences' price. Additionally, you may evaluate how the addition of MBX Biosciences to your portfolios can decrease your overall portfolio volatility.